Results 161 to 170 of about 28,066 (219)

The effect of PCSK9 inhibitors on cardiovascular outcomes in diabetic patients: a narrative review. [PDF]

Front Pharmacol
Khalid Sharafeldin AB, Aljundi NET, Hussain A, Alaraibi AJ, Butler AE.   +4 more
europepmc   +1 more source

From Disease Silos to Integrated Cardiometabolic Care: Diabetes, Vascular Disease, and Heart Failure

Journal of Diabetes, Volume 18, Issue 9, September 2026.
Zachary T. Bloomgarden, Yehuda Handelsman   +1 more
wiley   +1 more source

PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment. [PDF]

Front Cardiovasc Med
Lan J, Qiu Y, Wang S, Zhang Y, Cheng S, Chen S, Xing Y.   +6 more
europepmc   +1 more source

Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets. [PDF]

Front Med (Lausanne)
Ponte-Negretti CI, Lorenzatti A, Wyss-Quintana F, Alonso R, Méndez-Castillo M, Valdez-Tiburcio O, Ullauri-Solórzano VE, Ullauri-Valcárcel CY, Puente-Barragán A, Zárate-Correa LC, Prieto-Marín JG, Sangucho IAS, Vasconez-Gonzalez J, Ortiz-Prado E.   +13 more
europepmc   +1 more source

PCSK9 alleviates doxorubicin‑induced pyroptosis of cardiomyocytes. [PDF]

Mol Med Rep
Cui C, Zhao J, Li X, Huang S, Liu G, Xu X, Guo C, Zhao T, Du J, Li S, Wang X, Yang J.   +11 more
europepmc   +1 more source

Correction: Triglyceride-lowering therapies for hepatic steatosis: mechanisms, efficacy, and clinical perspectives

Frontiers in Pharmacology
Seyed Saeed Tamehri Zadeh, Peter P. Toth, Peter P. Toth, Maciej Banach, Maciej Banach   +4 more
doaj   +1 more source

"RAL" the LDLR to lysosomes for degradation. [PDF]

Life Metab
Guan Y, Huang Y, Li Z, Wang Y.
europepmc   +1 more source

Lifelong Genetic Inhibition of PCSK9 and Hepatic Safety.

JAMA Netw Open
Di Costanzo A, Pirona I, D'Erasmo L, Buonaiuto S, Colonna V, Via A, Tramontano D, Maiorca C, Arca M.   +8 more
europepmc   +1 more source

Discovery of Novel PCSK9-LDLR PPI Inhibitors by a Structural Modification Approach. [PDF]

Drug Dev Res
Zhu H, Zhang Z, Zhang L, Cao J, Zhang L.
europepmc   +1 more source

PCSK9 Inhibitor Attenuates Platelet TLR4 in ACS and TLR4 Blockers Prevent PCSK9-Mediated Platelet Activation. [PDF]

Acta Cardiol Sin
Qi L, Yuan M, Liu X, Liu T, Zhang Y, Chen K.   +5 more
europepmc   +1 more source